Skip to main content
European Commission logo print header

Novel catheter to reduce Urinary Tract Infections (UTIs)

Project description

Innovative urinary catheters to reduce infections and improve patients’ quality of life

Urinary catheters (UC) are used during medical interventions and treatment, for incontinence or urine retention in cases of spinal cord injury, prostate hypertrophy and many other conditions. UC are associated with a decline in the patients’ quality of life, frequent emergency visits and increased risk of infection both for patients and health care professionals. The EU-funded T-CONTROL project is developing an improved UC with a novel design and a special hydrophobic membrane material to address shortfalls of currently available UC. The goal of the project includes the clinical validation of the added value, product registration and launch.

Objective

T-Control is an innovative indwelling urinary catheter. Urinary Catheters (UC) are one of the most frequently used medical devices
on the market. They are used during medical interventions and treatment, as well as incontinence or urine retention in case
of spinal cord injury, prostate hypertrophy, weak muscle, and many other conditions.

There are several unmet needs related to currently used catheters. They cause a sharp decline of quality of life of the
patients, are linked to frequent emergency visits and increase substentially the risk of infection both for patients and health
care professionals. There are about 1,3 million cases in EU, causing 1,8 bn EUR direct cost and more than 14,000 deaths.

T-Control is addressing all the previously mentioned problems thanks to its novel design and a special hydrophobic membrane material, with patent approval both in EU and US, developed after 4 years of R&D.

T-Control will reduce additional days of hospitalization (leading to €1.14B savings in EU alone), but also guarantee the safety of health workers and decreasing continence related waste (sheets, gloves, diapers, catheters, bags…) representing around 29% of medical waste in non-acute hospitals.

Rethink Medical SL develops new medical solutions, mainly linked to nursing. It raised the interest of 16 stakeholders on the market (Letters of Support).

The feasibility study (SME Phase 1) shall address a financial plan, foreseeing all the costs and investments associated with commercializing our custom-made UC and the expected revenues. The study will also aim at assessing other important aspects such as IPR management, determine the best investment route for the growth stage, and conclude the best channels to reach customers and how we can best explain our difference from competition (prescribers, events, hospitals…). All these activities will lead to the ratification of a detailed business plan that will pave the way towards an effective market introduction.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

RETHINK MEDICAL SL
Net EU contribution
€ 50 000,00
Address
C/ PRACTICANTE IGNACIO RODRIGUEZ S/N - EDIFICIO PO II DEL CAMPUS UNIVERSITARIO DE TAFIRA
35017 LAS PALMAS DE GRAN CANARIA
Spain

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Canarias Canarias Gran Canaria
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00